05.16.25 -- The Technologies Propelling GLP-1 Analogues

Explore two case studies where lung cancer therapies were delivered to the lung by dry powder inhaler in a rat model and evaluated for efficacy, confirming that local delivery is a promising route.

Watch techniques like visual inspection and TOC sampling to assess surface residues, as well as discover the benefits and challenges of these practical methods to achieve effective residue validation.

Examine the benefits of controlled release, the application of PBPK modeling in controlled release formulation development, and how modified release products can be developed.

Is your company still using outdated methods for its QMS? It's time to evolve. Uncover how an integrated QMS can streamline operations, enhance compliance, and support your company's growth.

Review the need for digital quality management systems to ensure compliance as life science companies face rising FDA recalls.

A recent project applied process improvement methodology to the process validation step that ultimately provided not only an optimized, robust process but also an economic advantage.

Bispecific antibodies (bsAbs) are revolutionizing medicine by targeting two disease mechanisms simultaneously. Learn about an innovative platform offering excellent pairing and enhanced productivity.

Pharmaceutical excipients like mannitol enhance formulation stability, flowability, and compressibility, which are crucial for robust tablets. Read how these properties improve patient compliance.

Ready-to-use cartridges for GLP-1 applications offer safe, reliable self-administration. See how they can minimize complexities and better align with the stringent demands of modern manufacturing.

The newly developed G1-3 fermentation process makes use of short, straightforward fermentation regimes for optimized space time yield.

Reveal how one pharmaceutical facility overcame strict cross-contamination rules and space limits without costly building modifications to ensure operational continuity.

Explore how medical device companies aim to balance patient safety with environmental stability by offering bio-based UHMWPE, which reduces carbon footprints by up to 70%.